Alzheimer’s CSF 3-Plex Assay for Alzheimer’s Disease
Simultaneous measurement of multiple CSF biomarkers for AD
Proteome Sciences has developed a novel biomarker panel for simultaneous measurement of 3 signature peptide biomarkers in Alzheimer Disease (AD) patient Cerebrospinal Fluid (CSF) samples. The Alzheimer’s CSF 3-Plex Assay is intended for use in monitoring disease progression in AD patients, and potentially could be used as a diagnostic assay for AD.
| Applications |
Sample Types |
Species |
Analysis Method |
| *Alzhiemer's clinical analysis, early detection/prognostic |
CSF samples |
Human |
AQUA_SRM Peptide Mass Spectrometry |
* In development
The Alzheimer’s CSF 3-Plex Assay uses a highly reproducible and sensitive Selected Reaction Monitoring (SRM) mass spectrometry method coupled with heavy isotope-doped labeled peptide reference standards.
Learn more…
Alzheimer’s CSF 3-Plex Assay offers:
- Off-the-shelf Mass Spectrometry assay service available through ISO 9001:2008 accredited facility
- Focused panel of CSF biomarkers for early diagnosis and/or prognostic monitoring of AD
- Unique proprietary panel of signature peptide biomarkers
- Accurate, precise and reproducible results with absolute quantitation of markers
Alzheimer’s CSF 3-Plex Assay Biomarker List:
| Marker Protein |
Sample Types |
Species |
Analysis Method |
Disease Population Conc. Range |
| Cystain C |
CF |
Human |
AQUA-SRM |
1.3 nmol/L |
| TBC |
CSF |
Human |
AQUA-SRM |
200 pmol/L |
| Neurosecretory Protein VGF |
CSF |
Human |
AQUA-SRM |
TBC |
Background and Intended Use
There is currently no definitive diagnostic method for identifying patients with Alzheimer’s Disease other than postmortem analysis of brain tissue. In vivo brain imaging techniques coupled with assessment of cognitive and neuropsychological state are providing a better understanding of disease management but are unlikely to be widely applicable due to subjectivity in image analysis and learning effects in cognition tests. Development of a reliable and predictive test for diagnosis and monitoring of Alzheimer’s Disease using soluble biomarkers whilst a major need has proven elusive. Cystatin C, beta-2-microglubulin and Neurosecretory protein VGF have already been proposed as candidate biomarkers for monitoring Alzheimer’s Disease from human CSF samples (Carette et al. 2003). Proteome Sciences has developed a SRM (Selective Reaction Monitoring) mass spectrometry assay for the measurement of these biomarkers in CSF, and preliminary results are promising (Dayon et al. 2011). The assay is currently undergoing further validation to determine clinical sensitivity and specificity in a larger cohort.
References
